Month: May 2026

Adding to index shorts with S&P cash +30 handles:

* SPY ($SPY) $736.91

* QQQ ($QQQ) $707.94

Positions: Short SPY VS QQQ VS

Evidence of a consumer-led slowdown appearing today in the share prices of Lowes ($LOWE) (-$9), Home Depot ($HD) (-$5), Walmart ($WMT) (-$2) and Costco ($COST) (-$11).

Positions: None.

I have to travel this afternoon for a business dinner.

I will be leaving at around 2 p.m. and I won’t be around for the Nvidia ($NVDA) fireworks.

Positions: None.

Upside:

-IMVT +23% (earnings, color)

-POET +15% (Marex Securities Products builds 6% stake in POET)

-TATT +14% (earnings, color)

-EGHT +12% (earnings, guidance)

-RRGB +10% (earnings, guidance)

-IBRX +8.3% (US FDA Accepts sBLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease)

-CAVA +7.7% (earnings, guidance)

-AMC +5.1% (CEO Adam Aron bought 250K shares at $1.377/shr)

-MRVL +4.9% (multiple broker price target raises)

-STM +4.5% (Euro semi name strength)

-LPG +3.9% (earnings, color)

-MU +3.9% (momentum amid potential memory chip shortage)

-TJX +3.8% (earnings, guidance)

-VFC +3.4% (earnings, guidance)

-PSNL +3.3% (Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test)

-TOL +3.3% (earnings, guidance)

-ASML +2.9% (Euro semi name strength)

-SNDK +2.4% (memory stock strength with rising memory price concerns)

-DMAC +2.3% (announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial)

Downside:

-VIAV -8.7% (prices 11.1M shares at $45.00/shr)

-NWL -2.6% (Morgan Stanley Cuts NWL to Underweight from Equal Weight, price target: $3.50)

-HAS -2.2% (earnings, guidance)

-LOW -2.1% (earnings, guidance)

Positions: None.

Positions: None.

PIMCO: Hyperscaler spreads over Treasuries have widened, and they’ve widened compared to other investment grade companies as well. While they were about 15% cheaper in early 2025, they’re now 25% more expensive, showing the market is pricing in more risk.

Here’s a look at… pic.twitter.com/upGjshNKGP

— Sonali Basak (@sonalibasak) May 20, 2026

Position: None.

Virginia Governor Vetoes Marijuana Sales Legalization Bill After Lawmakers Rejected Her Amendments – Marijuana Moment

Position: None